Dr. Albornoz is an early career researcher who has training in neuroscience, immunology, and pharmacology. Prior to migrating to Australia, he completed a bachelor's in Biochemistry followed by a master’s degree in Chile, he then gained experience working in Chile as a research assistant in the Millennium Institute for Immunology and Immunotherapy, focusing on neurodegeneration and the immune response in the context of Multiple Sclerosis. Later, he was awarded a UQ international scholarship to undertake a Ph.D. at the Institute for Molecular Biosciences (IMB), under the supervision of Prof Matt Cooper, his Ph.D. project has assisted in the development of next-generation NLRP3 inflammasome inhibitors, and to validate NLRP3 as a druggable therapeutic target for Parkinson’s disease. He completed his Ph.D. in 2019 and continued his post-doctoral research studies under the supervision of Prof Trent Woodruff. A key focus of his current work is testing novel drugs in preclinical models and understanding the role of the peripheral innate immune response in neurodegenerative diseases including motor neuron disease (amyotrophic lateral sclerosis), Huntington's disease, and Parkinson's disease.
Prof. Arnold studied at Macquarie University before taking up research positions at the University of Sydney and University College London. He took up a continuing position at the University of Queensland in April, 2006.
Evan Bailey is a postdoctoral researcher in the Molecular and Systems Medicine Group at the School of Biomedical Sciences and Queensland Brain Institute. His current work focuses on the interplay between innate immune signaling and cellular metabolism in neurodegenerative diseases utilising his skills and experience in molecular genetics, cellular physiology and computational biology.
Evan started his career as a Research Assistant in the lab of Dr. Natasha Kumar at UNSW, Sydney, studying functional plasticity in chemoreceptive brainstem neurons in response to chronic hypercapnia (elevated CO2) before moving to UQ to pursue a PhD in evolutionary-developmental neuroscience. His PhD work under the supervision of Dr. Laura Fenlon and Dr. Rodrigo Suarez focused on the evolution of cellular mechanisms controlling neuronal differentiation and fate specification in the neocortex of marsupial and placental mamals, resulting in publications in Nature Communications and PNAS. Throughout his research career, Evan has had a keen interest in how cells establish and maintain their functional identity across a wide range of contexts and how homesostatic programs (e.g. energy metabolism) influence cell identity and phenotypic transitions.
I am an academic paediatric neurologist, clinical researcher, and specialist in acquired brain injury in children and adolescence. I studied at the University of Edinburgh and British Columbia before taking up my first academic position at the University of Calgary in 2002. Here I developed and directed the Traumatic Brain Injury and Concussion Research Program at the Alberta Children's Hospital and where I cemented my interest in the biology and treatment of children with brain injuries. I have extensive clinical research experience, devising and overseeing clinical trials in children both nationally and internationally. I moved to the Child Health Research Centre at the University of Queensland, Australia in October 2017 and joined the Queensland Paediatric Rehabilitation Service and Queensland Cerebral Palsy Rehabililation Centre to facilitate research into improving the health outcomes of children with acquired brain injury in Queensland and Australia.
My research focuses on the neurobiological signatures and treatment of subtle neurological dysfunction in mild traumatic brain injury and concussion, especially the behavioural and cognitive impairments that are found in post-concussion syndrome. I use multimodal neurological assessments to do this. My research explores combining neuroimaging and neurophysiological investigations, including perfusion studies using MRI (ASL-fMRI) and transcranial magnetic stimulation to help us understand the changes in the brain in children who are slow to recovery following a concussion. This is to help us develop and assess more effective and tailored treatments for children with concussion and traumatic brain injury. I explore novel therapies for children with persistent post-concussive symptoms in clinical trials including the use of neuraceuticals, pharmacotherapies, and non-invasive brain stimulation treatment.
I am the director of the newly-established KidStim Lab at the Child Health Research Centre. This is the first non-invasive neuromodulation facility aimed at improving the health outcomes of children with brain injury in Australia and is led by a mulitdisciplinary team of clinicians and scientists from Brisbane bring a unique clinical and scientific knowledge-base to help achieve our goals. Rehabilitation therapy in combination with repetitive transcranial direct current stimulation (rTMS) and other direct current stimulation modalities (e.g. tDCS) will be explored. It also offers the potential for treatment of the mood and behavioural disorders (e.g. depression and anxiety) commonly seen after brain injury but also so disruptive to the life of the normally developing teenager.
Dr Ben Barry is an allied health professional working clinically in aged care with Wesley Mission Queensland.
Dr Barry has a research background in adaptations of the nervous system to exercise and ageing. His research interests have progressed to health professional education, spanning digital health, interprofessional education and workforce development. Dr Barry's clinical work as a physiotherapist and exercise physiologist with a focus on healthy ageing links nicely with his PhD thesis on "Resistance training and movement control in older adults".
Dr Barry has extensive experience teaching allied health (exercise physiology), medical science and medical students. This has included coordinating degree programs and courses, leading teaching teams and discipline-wide curriculum reviews, expanding and enhancing clinical placement programs and student clinics, and innovations in online teaching of health professionals.
Dr Barry completed postdoctoral training in the Neurophysiology of Movement Laboratory at the Department of Integrative Physiology, the University of Colorado - Boulder USA, and subsequently worked for a decade at the School of Medical Sciences, The University of New South Wales, as well as holding an honorary appointment at Neuroscience Research Australia, before returning to The University of Queensland in 2017. He has a track record of external research funding and postgraduate research supervision as well as several teaching awards.
Australian Institute for Bioengineering and Nanotechnology
Professor
School of Electrical Engineering and Computer Science
Faculty of Engineering, Architecture and Information Technology
Availability:
Not available for supervision
Media expert
Markus graduated from the Vienna University of Technology in Technical Physics in 1995 and was awarded his Doctorate in 1999 after which he worked as postdoctoral research associate and then Assistant Professor at the Department of Radiodiagnostics, Medical University Vienna (AT). From 2004 he worked as Senior Researcher at the Donders Institute for Brain, Cognition and Behaviour (Radboud University Nijmegen, NL) and at the Erwin L. Hahn Institute for Magnetic Resonance Imaging (University Essen-Duisburg, DE). In 2014 he relocated to the University of Queensland to head the Ultra-high Field Human MR Research program at the Centre for Advanced Imaging and was awarded an ARC Future Fellowship. In 2019 he joined the School of Information Technology and Electrical Engineering as Full Professor MR Physics and Medical Imaging and has been appointed as Director for the National Imaging Facility – Queensland Node.
Dr Lizzie Beadle is a clinical psychologist, neuropsychologist, and researcher. Her research is focused on neuropsychological rehabilitation, changes to self-awareness and identity after brain injury, and use of technology in rehabilitation. She has practiced as a psychologist from acute through to community services. She is experienced in translation of research in to clinical practice. She is passionate about supporting a lifelong love of learning in students and clinicians. She is also passionate about supporting greater medical and lifestyle choice and control for individuals with disabilities.
Stefanie was awarded a PhD in Cognitive Psychology / Experimental Psychology in 2007, from the University of Bielefeld, Germany, and was subsequently awarded two awards for it (amongst them the National German Dissertation Award). She then took up a 1-year post-doc position with Prof Roger Remington at UQ. Subsequently, her work was supported by various fellowships from UQ and the ARC, allowing Stefanie to focus mainly on research from 2009 - 2018. Afterwards she was employed on a Teaching and Research position at UQ, where she is currently employed as an Associate Professor.
Electrophysiology of synaptic transmission, ion currents and central pattern generation in CNS neurones.
Current research focuses on the electrophysiology of central nervous system neurones using various in vitro slice and in vivo preparations, patch clamp techniques, imaging, molecular biology and computer modelling.
Projects include :
Neurobiology of motor control
Motor neuron disease
Synaptic transmission in the cochlear nucleus
Potassium currents in the brainstem and cerebellum
Stefan is a Staff Specialist in Neurology at the Princess Alexandra Hospital (PAH) and the Mater Centre for Neuroscience. He finished his training as neurologist in 2012.
He runs dedicated multiple sclerosis (MS) and Neuroimmunology clinics at the PAH, leading in modern MS therapies. Moreover, he has been at the forefront of advancing the field of neuroimmunology in Queensland, with establishment of dedicated neuroimmunology outpatient clinics at the RBWH and PAH, combining expertise from neurologists and immunologists in the care of this very complex group of disorders.
In addition to his busy, full-time clinical workload, Stefan has been involved as PI or CI in a range of clinical trials in the fields of MS, botulinum toxin, CIDP and Pompe’s disease. Additionally, he has performed and is involved in ongoing research projects of neuroimmunological disorders such as neuromyelitis optica, myasthenia gravis and autoimmune limbic encephalitis. He has been a member of the New Horizons study to assess prevalence of anti-neuronal antibodies in patients with new onset psychosis.
Prior to this, Stefan finished a PhD in the field of ‘Immunogenetics of Guillain-Barre Syndrome and Chronic inflammatory polyneuropathy’ at the University of Queensland in 2014. He also completed a doctoral thesis at the University of Heidelberg, Germany in 2002 in the field of T cell immunology. During this time, he has developed solid skills in bench-side immunological research.
Currently, he is neurological lead in a diverse group of clinicians and scientists investigating the role of antineuronal antibodies in neurological and psychiatric disease. He supervises 3 PhD students in the field of advanced imaging in autoimmune encephalitis and multiple sclerosis. He is currently building up a laboratory to test antineuronal antibodies using live cell assays.
Dr. Gabriela Bodea received her PhD in 2014 with highest honours (Summa cum laude) from the University of Bonn, Germany. Subsequently, Dr Bodea joined the Genome Plasticity and Disease group at the Mater Research Institute in Australia. Here, Dr. Bodea began investigating the role of LINE-1 retrotransposons, a class of mobile DNA elements colloquially referred to as "jumping genes", in creating genetic variability within neurons. In 2017, Dr. Bodea joined the Queensland Brain Institute, University of Queensland, where she is currently a Research Fellow in the Computational and Molecular Biology lab. Dr. Bodea's research aims to understand how the dynamic regulation of retrotransposons shapes neuronal identity in the mammalian brain and why certain neuronal subtypes are more susceptible to neurodegenerative and neuropsychiatric disorders. Dr Bodea's work has been supported by prestigious fellowships awarded by the German Research Foundation (DFG) and the NHMRC-ARC Dementia Research Development. Dr. Bodea has published in top journals such as Nature Neuroscience, Cell Reports, Genome Research, and Development. Dr Bodea has also been involved in the training and mentorship of MSc and PhD students and participated in course coordination and lecturing activities.
Dr Liviu-Gabriel Bodea is a brain immune cell biologist specialising in the functional interplay between microglia, the brain’s primary resident immune cells, and surrounding cell types, both in health and disease. He is a Research Fellow at the School of Biomedical Sciences, Faculty of Medicine, and is affiliated with the Clem Jones Centre in Ageing Dementia Research, Queensland Brain Institute.
Liviu was awarded his Dr.rer.nat. (PhD) title from the University of Bonn, Germany (2014), working in the group of Prof. Harald Neumann on projects related to microglia physiology. He then relocated to Australia as the Peter Hilton Early Career Fellow in Ageing Dementia Research (2014-2019) to continue his work with Prof. Jürgen Götz on the underlying mechanisms of neurodegenerative diseases such as Alzheimer’s and Frontotemporal dementia. He secured major extramural funding for his research (NHMRC Project Grant, NHMRC Ideas Grant, Dementia Australia Research Foundation Mid-Career Fellowship), and since July 2024, he has led the Microglia Metabolic Reprogramming and Proteostasis Research Team within the laboratory of Assoc. Prof. Karin Borges.
Liviu has significant experience in generating and analysing both in vivo and in vitro models (from stable cell lines and primary cultures to genetically modified mice). His work combines various biochemical and molecular techniques, ranging from high-resolution microscopy to omics (transcriptomics, proteomics) and bioorthogonal labelling to analyse newly synthesised proteins.
Liviu has extensive experience in guiding both undergraduate and postgraduate students into the wonders of scientific research :)
Complete List of Published Work: PubMed Bibliography
Funding and Awards
2024-2027 NHMRC Ideas Grant #2030460 (sole CI, ~AU$ 800,000)
2022-2024 Dementia Australia Research Foundation Mid-Carrier Research Fellowship (AU$ 375,000)
2022 The University of Queensland Research Stimulus Fellowship (AU$ 150,000)
2019 Emergency Services Queensland Philanthropic Support (AU$ 25,000)
2018-2021 NHMRC Project Grant #1147569 (CIB, ~AU$ 460,000)
2014-2019 Peter Hilton Early Career Research Fellowship in Ageing Dement (AU$ 500,000)
Research Impact, Leadership and Professional Activities
Dr. Bodea attracted >3,500 citations (h-index 15 @Google Scholar), including 6 articles with >100 citations (Google Scholar) and Web of Science 2x Highly Cited Papers. In 2021, Expertscape recognised Dr. Bodea as one of the top-rated researchers in the field of tauopathy, placing him in the top 0.8% of >142,000 published authors worldwide on tauopathies between 2012 and 2021. Further proving its impact, his work was cited in 22 patents.
Dr. Bodea's study on the microglial TYROBP in late-onset AD (Cell 2013, co-first author, former Highly Cited Publication @Web of Science) represents a milestone in the field, with >1700 citations (Google Scholar). He also revealed the complement-induced neurodegeneration of dopaminergic neurons following peripheral immune stimulation (JNeurosci 2014, first author). More recently, he coordinated studies that centred on the effect of Tau protein (molecule relevant for Alzheimer's disease) on protein synthesis (EMBO J 2019 and Acta Neuropathologica Communications 2021), the use of artificial amino acids and de novo proteome analysis for the investigation of memory (eLife 2020) and microglial physiology (STARProtocols 2023), and the role of neuronal PTEN enzyme in synaptic engulfment by microglia (Acta Neuropathologica 2020). He published authoritative reviews in the Journal of Neurochemistry (2017), Nature Reviews Neurology (2018), Nature Reviews Neuroscience (2018), and Brain Research Bulletin (2021).
Dr. Bodea has been a grant reviewer for Alzheimer’s Australia/Dementia Research Foundation (since 2016), MS Research Australia (since 2019), and NHMRC (since 2021). He was Lead Guest Editor for a Special Research Topic in Frontiers in Cellular Neuroscience (2023), is a member of the Reviewer Board for Frontiers in Cellular Neuroscience and was a member of the Reviewer Board for the International Journal of Environmental Research and Public Health, Mental Health section. He is an ad-hoc reviewer for various top-tier publications, ranging from Science to Trends in Cell Biology.
Dr. Bodea has mentored and supervised the daily activity of PhD students (2 completed, 1 current), Honours students (4 completed, all awarded First Class distinctions), 2 research assistants, and >15 other students on smaller projects. His PhD students received awards (e.g., the Alistair Rushworth Fellowship, Merck-QBI Best Student Publication Award, Best Oral Presentation). Both his completed PhD students continue with academic careers: Dr. Joey Benetatos, following a successful post-doctoral training in the Fraenkel Lab (MIT, USA), is currently pursuing his second post-doctoral position in the Prof. Loren Looger group (UCSD, USA), and Dr. Harrison T Evans is holding an Alzheimer's Association Postdoctoral Fellowship and is the Leon Levy Fellow in the Prof. Eric Klann lab (NYU, USA).
School of Electrical Engineering and Computer Science
Faculty of Engineering, Architecture and Information Technology
Availability:
Available for supervision
Dr Steffen Bollmann joined UQ’s School of Electrical Imaging and Computer Science in 2020 where he leads the Computational Imaging Group. The Group is developing computational methods to extract clinical and biological insights from magnetic resonance imaging (MRI) data. The aim is to make cutting-edge algorithms and tools available to a wide range of clinicians and researchers. This will enable better images, faster reconstruction times and the efficient extraction of clinical information to ensure a better understanding of a range of diseases. Dr Bollmann was appointed Artificial Intelligence (AI) lead for imaging at UQ’s Queensland Digital Health Centre (QDHeC) in 2023.
His research expertise is in quantitative susceptibility mapping, image segmentation and software applications to help researchers and clinicians access data and algorithms.
Dr Bollmann completed his PhD on multimodal imaging at the University Children’s Hospital and Swiss Federal Institute of Technology (ETH) Zurich, Switzerland.
In 2014 he joined the Centre for Advanced Imaging at UQ as a National Imaging Facility Fellow, where he pioneered the application of deep learning methods for quantitative imaging techniques, in particular Quantitative Susceptibility Mapping.
In 2019 he joined the Siemens Healthineers collaborations team at the MGH Martinos Center in Boston on a one-year industry exchange where he worked on the translation of fast imaging techniques into clinical applications.
At the age of 15 I thought that I would like to develop new treatments for diseases where there is a need. After studying Biology in Germany and while working as a post-doctoral fellow with Professor Raymond Dingledine at Emory University, I became passionate about epilepsy. When starting my own laboratory at Texas Tech University, I began to investigate impairments in energy metabolism in epilepsy and potential new treatments to address energetic deficiencies. In 2011, I moved to UQ and have since enjoyed the many opportunities working with many talented students and professionals and within the globally highly respected Australin epilepsy community.
Recent research:
Among many other projects, my lab has characterized several metabolic alterations and impairments in energy metabolism in epilepsy (1, 2) and Motor Neuron Disease (1). In brain areas that can generate seizures, cytosolic and mitochondrial metabolism of glucose is impaired (1), which can lead to energy deficits and may trigger seizures. From a biochemical standpoint, auxiliary fuels such as ketone bodies and medium chain fatty acids derived from medium chain triglyceride (MCTs) are well suited to improve energy levels. We have also shown that different MCTs, including triheptanoin, when added to normal diets can prevent seizure generation in seizure models (reviewed here 1, 2) and prevent motor neuron death in an MND model (1).
Our latest research aims to increase glucose transport into brain cells for glucose transporter 1 deficiency and epilepsy.
Research in the Bredy laboratory is aimed at elucidating how the genome is connected to the environment through epigenetic modifications, and how this relationship shapes brain and behaviour throughout life. The group is particularly interested in how epigenetic mechanisms, including DNA methylation, histone modifications. the activity of non-coding RNAs, and RNA modification regulate the formation and maintenance of associative fear-related memory.
Dr. Brownsett is a Speech Pathologist and neuroscientist. Trained initially in the UK as a Speech and Language Therapist, she advanced her expertise with a PhD in Clinical Neuroscience from Imperial College, London. Her doctoral research, employing functional brain imaging (fMRI), provided critical insights into the interaction between domain-general and language-specific brain networks, particularly in healthy older adults and individuals recovering from post-stroke aphasia. At the Queensland Aphasia Research Centre, she leads the ‘Imaging Predictors’ and ‘Aphasia TechHub’ groups, pushing the boundaries of research on neural markers and the use of technology in communication.
Dr. Brownsett's research interests are broad and impactful. She investigates the progression and extent of language difficulties in patients with brain injuries beyond stroke, including those with epilepsy and brain cancer. She explores the interplay between general cognitive brain networks and task-specific networks, seeking to understand and enhance recovery mechanisms. Her work also focuses on identifying neurobiological predictors of aphasia recovery, the effects of premorbid brain health on post-stroke language recovery, and the reorganization of language networks following neurosurgery.
Pioneering the integration of technology into therapy, Dr. Brownsett co-developed an innovative therapy application as part of the Listen-In trial, utilizing gamification to enhance engagement in high-dose aphasia therapy. She now leads the Aphasia Tech Hub, which supports individuals with aphasia to use and access technology. Her team, including those with lived experience of aphasia, adapts and creates communication-accessible guidance for using technology and provides tailored consultations to improve technology access.
Dr. Brownsett's dedication to involving people with aphasia in her research has earned her numerous accolades, including the National Health and Medical Research Council Consumer Engagement Award and the UK Stroke Forum Conference's Patient, Carer, and Public Involvement Winner award. She is a key member of the Living Stroke Guidelines initiative, ensuring clinical management of stroke is informed by the latest evidence. Through her innovative research and commitment to inclusive practices, Dr. Brownsett continues to contriute to advancing the field of aphasia recovery and neuroscience.
Professor Burne is a leading Australian researcher in the field of biological psychiatry. Prof. Burne has >150 peer reviewed publications, which have attracted over 8500 citations (H-index 50). His research impact is evident by his 11 papers with >200 citations, with two recognised as Web of Science ‘Highly Cited Papers’. Together with collaborators he has been awarded >$8 million in research funding. Since 2003 he has supervised 17 PhD students, and 28 honours students Prof. Burne has a broad background in behavioural neuroscience, with specific training and expertise in animal models. As a Professorial Research Fellow with the Queensland Centre for Mental Health Research and Group Leader at the Queensland Brain Institute (QBI) the focus of his research includes cognitive testing in rodent models of neuropsychiatric disorders, such as schizophrenia, as well as psychopharmacological studies and research on clinical populations. As a CI on several university- and NHMRC-funded grants, he has helped establish infrastructure at QBI for behavioural assessment and methods of automated operant-based cognitive tests in rodents. Prof. Burne is a past president of Biological Psychiatry Australia, he is the Queensland representative for the Australasian Neuroscience Society, and he is a member of the NHMRC Animal Welfare Committee.
Prof. Burne’s group studies brain development and behaviour in animal models to learn more about neuropsychiatric diseases, such as schizophrenia. Research is focused on investigating the underlying biological basis for schizophrenia, with the goal of finding public health interventions that will alleviate the burden of this disease. The group has been exploring the impact of developmental vitamin D (DVD) deficiency on brain development, the impact of adult vitamin D deficiency on brain function and behaviour, and the neurobiological affects of having an older father. More recently his group has been focussed on assessing cognitive function in rodents. Prof. Burne’s research is carried out in close collaboration with Professors John McGrath and Darryl Eyles, in a multidisciplinary team. Together they have an integrated research program using a broad range of neuroscientific techniques to explore potential causes of schizophrenia. There is a particular focus on early life, nongenetic risk factors and the team has skills in epidemiology, psychiatry, neuroanatomy, molecular biology, developmental biology and behavioural neuroscience. The Burne group is currently developing animal models related to risk factors for schizophrenia and autism.
Dr Fernanda Cardoso is a Brazil-born Australian researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.
Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.
Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.
